| Literature DB >> 29379199 |
Rhamy Zeid1, Matthew A Lawlor1, Evon Poon2,3, Jaime M Reyes1, Mariateresa Fulciniti1,4, Michael A Lopez1,4, Thomas G Scott1, Behnam Nabet1, Michael A Erb1, Georg E Winter1, Zoe Jacobson1, Donald R Polaski1, Kristen L Karlin5, Rachel A Hirsch5, Nikhil P Munshi1,4, Thomas F Westbrook5, Louis Chesler2,3, Charles Y Lin6,7, James E Bradner8,9,10.
Abstract
Amplification of the locus encoding the oncogenic transcription factor MYCN is a defining feature of high-risk neuroblastoma. Here we present the first dynamic chromatin and transcriptional landscape of MYCN perturbation in neuroblastoma. At oncogenic levels, MYCN associates with E-box binding motifs in an affinity-dependent manner, binding to strong canonical E-boxes at promoters and invading abundant weaker non-canonical E-boxes clustered at enhancers. Loss of MYCN leads to a global reduction in transcription, which is most pronounced at MYCN target genes with the greatest enhancer occupancy. These highly occupied MYCN target genes show tissue-specific expression and are linked to poor patient survival. The activity of genes with MYCN-occupied enhancers is dependent on the tissue-specific transcription factor TWIST1, which co-occupies enhancers with MYCN and is required for MYCN-dependent proliferation. These data implicate tissue-specific enhancers in defining often highly tumor-specific 'MYC target gene signatures' and identify disruption of the MYCN enhancer regulatory axis as a promising therapeutic strategy in neuroblastoma.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29379199 PMCID: PMC6310397 DOI: 10.1038/s41588-018-0044-9
Source DB: PubMed Journal: Nat Genet ISSN: 1061-4036 Impact factor: 38.330